Please assess the completion status of the following clinical trial:

Trial Title: Dendritic Cell Vaccine in HIV-1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HIV infection~* CD4 \> 450 x 10 6 /L~* baseline VL \>10,000 c/ml before any HAART~* Part I, patients off HAART at least during 6 months~* Part II, Patients on HAART with PVL \< 200 copies/ml at least during 6 months~* Written informed consent .~Exclusion Criteria:~* Patients with failure to HAART~* Patients with B or C symptoms (CDC classification 1993).~* Age \< 18 years old.~* Pregnant or breastfeeding women~* Patients with baseline creatinin \> 2.5 mg/dl~* Patients with baseline GOT/GPT \> 250 UI/L

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pulsed dendritic cells untreated patients (Type: ACTIVE_COMPARATOR): Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
- non pulsed dendritic cells untreated patients (Type: PLACEBO_COMPARATOR): None
- pulsed dendritic cell treated patient (Type: ACTIVE_COMPARATOR): treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
- pulsed dendritic cell in treated patients (Type: ACTIVE_COMPARATOR): patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
- non pulsed dendritic cells (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).